1027232-41-2

Basic information

• Product Name: Methyl-[(R)-1-(methyl-{(R)-1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-carbamoyl)-2-naphthalen-2-yl-ethyl]-carbamic acid tert-butyl ester
• Synonyms: Methyl-[(R)-1-(methyl-{(R)-1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-carbamoyl)-2-naphthalen-2-yl-ethyl]-carbamic acid tert-butyl ester
• CAS NO: 1027232-41-2
• Molecular Weight: 600.802
• Mol File: 1027232-41-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Methyl-[(R)-1-(methyl-{(R)-1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-carbamoyl)-2-naphthalen-2-yl-ethyl]-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl-[(R)-1-(methyl-{(R)-1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-carbamoyl)-2-naphthalen-2-yl-ethyl]-carbamic acid tert-butyl ester(1027232-41-2)
• EPA Substance Registry System: Methyl-[(R)-1-(methyl-{(R)-1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-carbamoyl)-2-naphthalen-2-yl-ethyl]-carbamic acid tert-butyl ester(1027232-41-2)

Safety Data

• Hazardous Substances Data: 1027232-41-2(Hazardous Substances Data)

Upstream product

• 1026432-09-6 methyl-{1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 37553-65-4 N-tert-butoxycarbonyl-N-methyl-D-phenylalanine 
• 73579-08-5 Methyl-(1-methyl-[4]piperidyl)-amin 

Downstream Products

• 1025953-07-4 N-methyl-2-methylamino-N-{1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-3-naphthalen-2-yl-propionamide 

Relevant articles and documents

The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency

In order to obtain more potent growth hormone secretagogues, a comparison of ipamorelin and NN703 suggested the addition of a polar group at the C-terminus of NN703. A study was conducted using constrained amines for this purpose. Here, substituted 4-piperidinylamino- and 4-dimethylaminopiperidino-substitutents were found to give the most active compounds. A replacement of the 4-dimethylaminopiperidino-substituent with 4-hydroxypiperidino resulted in a series of compounds, which showed in vitro activity with EC50 values in the low nanomolar range, and favourable kinetic properties, such as 40% oral bioavailability. The most promising compound was also tested in a swine in vivo model, resulting in a growth hormone level with a Cmax of over 40 ng mL-1.